RAPT - Company ID 0001673772
The table below shows RAPT Therapeutics, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $12.03M | $12.34M | $12.04M | $13.34M | $22.64M | $24.78M |
| SG&A |
RAPT Therapeutics, Inc. reported annual revenue of $0.00 for fiscal year 2023. That is down 100.0% from $1.53M in fiscal 2022. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $7.34M |
| $7.20M |
| $7.22M |
| $6.45M |
| $6.69M |
| $7.74M |
| Operating income | -$19.37M | -$19.54M | -$19.27M | -$19.79M | -$29.33M | -$32.52M |
| Income tax | - | - | - | - | - | - |
| Net income | -$17.58M | -$17.64M | -$17.16M | -$18.43M | -$27.66M | -$30.52M |
| EPS (diluted) | -$0.65 | -$0.65 | -$0.08 | -$3.79 | -$5.69 | -$0.79 |